Estimates Revisions Viking Therapeutics, Inc.
Stocks
VKTX
US92686J1060
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-09-01 EDT
|
5-day change | 1st Jan Change | ||
| 33.67 USD | +2.72% |
|
+1.32% | -4.29% |
| 08-03 | Viking Therapeutics' VK2735 Drives Substantial Optionality, Oppenheimer Says | MT |
| 07-30 | Viking's Obesity Treatments Advance as New Data, Trials Loom, Oppenheimer Says | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | - | - | ||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Stocks
- VKTX Stock
- Consensus Viking Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
